NaDeNo is a leading brand in the field of nanoscience, specializing in the development of a proprietary drug delivery platform. With a focus on overcoming the challenges associated with delivering hard-to-deliver drugs, NaDeNo aims to unleash the potential of hydrophobic small molecule drugs.

The majority of failures in small molecule drug development are attributed to low water solubility, but NaDeNo's technology platform of nanoparticles offers a solution. These nanoparticles have biodegradable and biocompatible properties, making them ideal for encapsulating hydrophobic drugs. They enable controlled drug release and have a high drug load capacity.

NaDeNo's technology also allows for tailored surface properties and active targeting, enhancing the efficacy of the drugs. The brand offers tailored nanoformulations to pharmaceutical and biotechnology companies, providing advanced solutions for drug delivery challenges.

NaDeNo's lead candidate, PACAB-002, is a nanoformulation of cabazitaxel encapsulated in polymeric nanoparticles. Preclinical data have shown improved treatment effects and reduced side effects compared to the free drug. With a management team experienced in drug development and nanomedicine, NaDeNo is at the forefront of innovative drug delivery solutions.